<DOC>
	<DOCNO>NCT02406209</DOCNO>
	<brief_summary>This randomize , multi-center , investigator mask , comparator control study . The purpose study determine efficacy safety NS2 patient non-infectious acute anterior uveitis . Subjects randomize 1:1:1 receive multiple dos NS2 0.5 % , NS2 0.5 % Pred Forte® 1 % , Pred Forte® 1 % . Free aldehyde think related inflammatory disease uveitis . NS2 , small molecule aldehyde trap , may decrease inflammation lower aldehyde level .</brief_summary>
	<brief_title>A Safety Efficacy Study NS2 Patients With Anterior Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Noninfectious anterior uveitis Grade 1 Grade 3 anterior chamber cell count Subjects must Intraocular pressure &lt; 25 mmHg baseline may administer maximum 1 topical medication control Intraocular pressure study eye . Visual acuity ≥ 20/200 study eye Severe/serious ocular pathology Active intermediate posterior uveitis . Previous anterior uveitis episode study eye within 4 week Visit 1 Oral corticosteroid within 14 day Visit 1 Intravitreal subTenon corticosteroid treatment study eye within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>uveitis</keyword>
	<keyword>acute uveitis</keyword>
	<keyword>anterior uveitis</keyword>
	<keyword>NS2</keyword>
	<keyword>Aldeyra</keyword>
	<keyword>prednisolone acetate</keyword>
</DOC>